Multiple Myeloma

The FDA has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval of dose-adjusted carfilzomib in patients with myeloma.

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the potential of quadruplets in the treatment of patients with multiple myeloma.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Adding daratumumab to lenalidomide and dexamethasone reduced the risk of disease progression or death by 45% compared with lenalidomide/dexamethasone alone in newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the data behind the frontline approval of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) in multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses transplant and maintenance for the treatment of patients with high-risk multiple myeloma.

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

Among new advances in multiple myeloma, high-dose chemotherapy and allogeneic stem cell transplant remain the go-to frontline treatment for patients with newly diagnosed multiple myeloma.

The FDA has granted a priority review to a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Bita Fakhri, MD, MPH, shares her insight on the treatment of patients with newly diagnosed multiple myeloma.

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

The FDA has approved the next-generation sequencing assay clonoSEQ as a test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia or multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

The FDA has approved a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.